Avantor, Inc.

Avantor, Inc.(AVTR)股票分析

$15.700

+0.151 (+0.96%)收盤時

Loading chart…
最高
16.000
開盤
15.610
成交量加權均價
15.77
成交量
8.05M
市值
14.55B
最低
15.610
成交金額
126.98M
企業價值/稅息折舊攤銷前利潤(TTM)
15.39

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company's segments include Bioscience & Medtech Products and VWR Distribution & Services. Through these segments, it provides materials and consumables, equipment and instrumentation and services and specialty procurement to customers in biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and others.

AI 分析 of Avantor, Inc. (AVTR)

買進

Avantor Inc is a good buy right now due to its current price of $15.67 being below the average analyst target price of $16.75, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +36.74%, reflecting positive momentum. However, the main risk is its negative net income margin of -43.84% reported in Q3 2025, which raises concerns about profitability.

估值指標

Avantor, Inc.(AVTR)目前預期本益比為 16.86,5 年平均預期本益比為 18.35。

預期本益比

合理
5 年均值 P/E
18.35
目前P/E
16.86
高估
23.29
低估
13.42

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
17.57
目前EV/EBITDA
15.39
高估
31.25
低估
3.90

預期股價營收比

合理
5 年均值 P/S
1.94
目前P/S
1.55
高估
2.53
低估
1.36

Alphio AI 對 AVTR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%AVTR

$16.34

情境價格

基

基準

基準 · 50%AVTR

$14.73

情境價格

悲

悲觀

悲觀 · 25%AVTR

$12.25

情境價格

持有 AVTR 的大戶

Y

Yacktman Asset Management LP

+ 持有AVTR

+5.83%

3個月報酬率

A

Arlington Value Capital, LLC

+ 持有AVTR

+0.95%

3個月報酬率

F

First Pacific Advisors, LP

+ 持有AVTR

+0.20%

3個月報酬率

G

Greenhaven Associates Inc

+ 持有AVTR

-0.52%

3個月報酬率

S

Southeastern Asset Management, Inc.

+ 持有AVTR

-4.57%

3個月報酬率

N

NewSouth Capital Management, Inc.

+ 持有AVTR

-4.63%

3個月報酬率

事件時間軸

2026-09-21 (ET)

06:30:00

Avantor Appoints Todd Garner as EVP and CFO

2026-07-29 (ET)

17:00:00

Federal Reserve Holds Rates Steady, Major Indices Drop Significantly

12:30:00

Dow Jones Drops 874.35 Points as Oil Prices Surge

06:30:00

Raises FY26 Organic Revenue View to Down 0.5% to Up 0.5%

06:30:00

Company Reports Q2 Revenue of $1.69B, Exceeding Expectations

資訊

AVTR 常見問題 —— 由 Alphio AI 解答

Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company's segments include Bioscience & Medtech Products and VWR Distribution & Services. Through these segments, it provides materials and consumables, equipment and instrumentation and services and specialty procurement to customers in biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Avantor Inc is a good buy right now due to its current price of $15.67 being below the average analyst target price of $16.75, indicating potential upside. Additionally, the stock has shown a strong year-to-date change of +36.74%, reflecting positive momentum. However, the main risk is its negative net income margin of -43.84% reported in Q3 2025, which raises concerns about profitability.

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易